Universität zu Köln

Zagadailov, Erin A., Corman, Shelby, Chirikov, Viktor, Johnson, Courtney, Macahilig, Cynthia, Seal, Brian, Dalal, Mehul R., Broeckelmann, Paul J. and Illidge, Tim (2018). Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk. Lymphoma, 59 (6). S. 1413 - 1420. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians' choice chemotherapy. Median PFS was significantly longer (27.0 months vs. 13.4 months; p=.0144) and 12-month OS survival greater (78.1% vs. 65.9%; p=.0129) with BV compared to chemotherapy. Documented adverse events included leukopenia (12.8%) and peripheral neuropathy (8.7%) for BV and leukopenia (12.1%), anemia (5.2%) and diarrhea (5.2%) for chemotherapy. In this real-world study, rrHL patients treated for relapse after ASCT with BV had longer median PFS and 12-month OS than patients receiving chemotherapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zagadailov, Erin A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Corman, Shelby UNSPECIFIED UNSPECIFIED UNSPECIFIED Chirikov, Viktor UNSPECIFIED UNSPECIFIED UNSPECIFIED Johnson, Courtney UNSPECIFIED UNSPECIFIED UNSPECIFIED Macahilig, Cynthia UNSPECIFIED UNSPECIFIED UNSPECIFIED Seal, Brian UNSPECIFIED UNSPECIFIED UNSPECIFIED Dalal, Mehul R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Illidge, Tim UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-200731
DOI:	10.1080/10428194.2017.1382698
Journal or Publication Title:	Leuk. Lymphoma
Volume:	59
Number:	6
Page Range:	S. 1413 - 1420
Date:	2018
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NON-INFERIORITY TRIAL; DOSE-INTENSIFICATION; ANTITUMOR-ACTIVITY; PROGNOSTIC MODEL; OPEN-LABEL; DISEASE; PROGRAM Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/20073